"PHILADELPHIA, July 15, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma announces that they have submitted an application for orphan drug designation to the European Medicines Agency (EMA) for Alferon N Injection(R), an experimental therapeutic, to treat Middle East Respiratory Syndrome (MERS). The EMA has determined the application to be valid, and the Committee for Orphan Medicinal Products (COMP) has initiated the official review process. It is anticipated that the COMP will give an opinion on the application within the next 90 days. There are significant benefits for achieving Orphan Designation, including eligibility for grants from EU and Member State programs. Designated orphan medicines are assessed for marketing authorization centrally in the European Union with reductions/waivers in the fees and costs of the overall regulatory process."
If acceptance is obtained- may be very positive.
we will know in 90 days = 3 months from July 2015 = i.e by Oct-Nov 2015